Projects In Knowledge

The Advanced Certificate Program in Multiple Sclerosis Management III

The past few years have seen exciting developments in understanding the pathophysiology and disease processes of MS and new diagnostic methodologies. Many emerging therapeutic agents are now in development with new data rapidly emerging.

The first oral therapeutics in MS have completed phase III trials and may soon become available. This outstanding free program offers you an excellent opportunity to keep current on all of these developments. Curriculum I courses present an overview of diagnostic and management strategies for MS patients, focusing on cutting-edge topics. Curriculum II presents more advanced courses that build on new scientific developments and the topics covered in Curriculum I. Curriculum III showcases important journal articles published in late 2009 through 2010, provides four new case studies featuring common clinical issues not discussed in the last two curricula, two podcasts that highlight presentations from the 2010 ECTRIMS and the 2011 AAN annual meetings, and a webcast that reviews new knowledge about potential MS risk factors and their clinical implications.

Featuring the very latest state-of-the-science information about MS diagnosis and treatment, this free online curriculum offers CME, CE, and CPE credit to neurologists and other clinicians who care for patients with MS.

New curriculum courses are continuously made available online throughout the year. Complete all courses by July 2011, and receive a certificate of advanced study.

The Advanced Certificate Program in Multiple Sclerosis Management III brings to you a community of experts to help you provide your patients with the best treatment outcomes possible....more

F. Lublin, MD

A. Miller, MD

The Advanced Certificate Program: Multiple Sclerosis Management II

The past few years have seen exciting developments in understanding the pathophysiology and disease processes of MS and new diagnostic methodologies. Many emerging therapeutic agents are now in development with new data rapidly emerging.

Curriculum I courses present an overview of diagnostic and management strategies for MS patients, focusing on cutting-edge topics. Curriculum II presents more advanced courses that build on new scientific developments and the topics covered in Curriculum I.

Featuring the very latest state-of-the-science information about MS diagnosis and treatment, this free online curriculum offers CME, CE, and CPE credit to neurologists and other clinicians who care for patients with MS.

New curriculum courses are continuously made available online throughout the year. Complete all courses by July 2010, and receive a certificate of advanced study....more

F. Lublin, MD

A. Miller, MD

The Advanced Certificate Program in Multiple Sclerosis Management

Fred D. Lublin, MD, and Aaron Miller, MD, co-chair this free, yearlong CME/CE program offering state-of-the-science information on the diagnosis, treatment, and management of multiple sclerosis (MS). Curriculum topics include the genetic basis of MS, the role of specific environmental factors in the pathophysiology of the disease, the importance of early treatment, novel therapies on the horizon, findings from recent clinical trials, and practical management strategies. Learn more and enroll today!...more

F. Lublin, MD

A. Miller, MD

Multiple Sclerosis 2010 Edition

This free, interactive CME/CE textbook provides comprehensive coverage of important MS-related topics, supplemented by hyperlinks to external multimedia resources such as illustrations, videos, journal articles, and other resources, that enhance understanding of relevant issues. ...more

B. Cohen, MD

Parkinson's Disease Edition:
Early Diagnosis and Management

Parkinson’s disease is traditionally diagnosed clinically based on classic motor symptoms of tremor, rigidity, bradykinesia, and postural instability. However, it is increasingly recognized that motor symptoms are only one manifestation of this chronic neurodegenerative disease—and a late manifestation at that. This chapter of the Parkinson's Disease Edition of the Living Medical Textbook describes the early symptoms of Parkinson’s disease, the underlying pathophysiology behind them, and available treatments for early Parkinson’s disease. Hyperlinks throughout the chapter lead the reader to more detailed and specific information on these topics from a variety of sources on the Internet in a multitude of formats. This first chapter sets the stage for a discussion of clinical trials and the neuroprotective potential of monoamine oxidase type B inhibitors in the management of early Parkinson’s disease. ...more

R. Hauser, MD, MBA

Multiple Sclerosis — Recognizing and Treating Multiple Sclerosis in the Primary Care Setting-Case Study

Recognizing clinically isolated syndrome (CIS) and differentiating it from clinically definite multiple sclerosis poses several challenges for primary care physicians. Once a diagnosis has been made, the clinician must then decide whether or not to treat the patient and, if so, with what. The practical issues involved in diagnosing and managing CIS are illustrated in this case study of a 33-year old man presenting with numbness and tingling from his feet up to the left side of his abdomen and upper back. ...more

K. Kennedy, MN, ARNP

Multiple Sclerosis — Recognizing and Treating Multiple Sclerosis in the Primary Care Setting

This CME/CE on-demand audio podcast features presentations from a recent live lecture and workshop, held in Seattle, WA, that focused on the management of multiple sclerosis (MS) in the primary care setting. Join Kate E. Kennedy, MN, ARNP, and Sylvia M. Lucas, MD, PhD, who have particular expertise in caring for patients with MS, as they discuss practical strategies on diagnosis and disease management that primary care clinicians can immediately incorporate into practice. ...more

K. Kennedy, MN, ARNP

S. Lucas, MD, PhD

Multiple Sclerosis — A Sea Change in MS Treatment — The Potential of Small Molecules

Recent advances in understanding the pathogenesis of multiple sclerosis and its relation to treatment, the importance of early intervention, and the use of novel small-molecule therapies are resulting in expanded treatment options and new hope for patients with this debilitating disease. Please join a panel of neurology experts at A Sea Change in MS Treatment—The Potential of Small Molecules to discuss these exciting new developments and the evolving strategies and controversies in optimizing outcomes for patients with multiple sclerosis....more

B. Cohen, MD

Multiple Sclerosis — Case Study: Development of Neurologic Symptoms in a Patient Treated with Disease Modifying Monoclonal Antibody Therapy

Suhayl Dhib-Jalbut, MD, describes a 45-year-old woman who develops signs and symptoms of what could be either progressive multifocal leukoencephalopathy (PML) or a new MS relapse while receiving treatment with natalizumab. Dr. Dhib-Jalbut illustrates the appropriate evaluation and workup needed to distinguish between these two diagnostic entities, and also reviews strategies for managing PML once a diagnosis is confirmed....more

F. Lublin, MD

Multiple Sclerosis — Recognizing and Treating Multiple Sclerosis in the Primary Care Setting-Case Study

K. Kennedy, MN, ARNP

Multiple Sclerosis — Expert Insight Into: A Prospective Open-Label Study of Endovascular Treatment of Chronic Cerebrospinal Venous Insufficiency. (Part 3 of Series)

Anne H. Cross, MD, discusses the results of the first study that explored percutaneous transluminal angioplasty (PTA) treatment of chronic cerebrospinal venous insufficiency (CCSVI), commenting on the limitations of this trial, the possible role of CCSVI in the pathogenesis of MS and the potential benefit of treating these obstructions with PTA....more

A. Cross, MD

Multiple Sclerosis — Case Study: SPMS with Walking Impairment and Paroxysmal Dysarthria

Robert P. Lisak, MD, FAAN, FRCP, illustrates how to manage paroxysmal symptoms and gait impairment—two common problems in MS—in this case study of a 54-year-old physician with secondary-progressive multiple sclerosis (SPMS). Comprehensive management of MS requires attention to these symptoms, which interfere with functioning and quality of life and can persist for decades....more

A. Miller, MD

Multiple Sclerosis — Expert Insight Into: A Placebo-Controlled Trial of an Oral Immunomodulator in Relapsing Multiple Sclerosis (Part 2 of Series)

Fred D. Lublin, MD, discusses the efficacy and safety results of a double-blind, placebo-controlled, phase 3 clinical trial that treated relapsing-remitting MS (RRMS) patients with daily fingolimod for 24 months. Fingolimod, an oral immunomodulatory drug and the first orally available therapy for RRMS to be accepted for review by the FDA, has shown promise in phase 2-3 clinical trials....more

F. Lublin, MD

Multiple Sclerosis — Managing Symptoms in Multiple Sclerosis

NEW CHAPTER
Many patients with multiple sclerosis (MS) live with symptoms that can increase disability and reduce quality of life. Clinicians should review and address these symptoms at each visit to ensure a comprehensive approach to the management of MS. This chapter of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition reviews the management of a number of common symptoms: spasticity, gait impairment, fatigue, cognitive impairment, depression, and bladder dysfunction....more

B. Cohen, MD

Parkinson's Disease — MAO-B Inhibitors in Parkinson's Disease: Evaluating the Evidence for Neuroprotection

Do monoamine oxidase type B (MAO-B) inhibitors modify the course of early Parkinson’s disease (PD)? Has the in vitro and preclinical evidence of neuroprotective activity for this class of drugs been borne out in clinical trials? These questions have been debated for at least 2 decades, and as yet, there is no clear consensus. Nonetheless, these remain important questions to consider because where you stand and how you interpret the data should affect how and when you use MAO-B inhibitors in the care of your PD patients. Find out more in the third chapter of this Living Medical Textbook, “MAO-B Inhibitors in Parkinson’s Disease: Evaluating the Evidence for Neuroprotection.”...more

R. Hauser, MD, MBA

Multiple Sclerosis — The Advanced Certificate Program in Multiple Sclerosis Management III

F. Lublin, MD

A. Miller, MD

Multiple Sclerosis — Expert Insight Into: The Natural History of Primary Progressive Multiple Sclerosis (Part 1 of Series)

Join Aaron E. Miller, MD, as he shares his insights into the results of a large retrospective study of the natural history of primary progressive MS (PPMS). PPMS is rare, currently untreatable, and offers the worst prognosis of the MS disease forms; therefore, it has been difficult to accurately determine the rate at which disability progresses in this disease course....more

A. Miller, MD

Multiple Sclerosis — Expert Insight Into: The Relation Between Inflammation and Neurodegeneration in Multiple Sclerosis Brains

Dr. Suhayl Dhib-Jalbut reviews a study that analyzed the interdependence of inflammation, neurodegeneration, and disease progression in various multiple sclerosis stages in relation to lesional activity and clinical course, with a particular focus on progressive multiple sclerosis....more

S. Dhib-Jalbut, MD